[In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates].
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of faropenem (FRPM) more compared with those of various oral beta-lactams against 15 isolates each of 6 species of microorganism. FRPM possessed potent in vitro antibacterial activity against both aerobic and anaerobic Gram-positive bacteria tested. FRPM showed the same activity as new oral cephems such as cefdinir, cefditoren and cefcapene against all Gram-negative bacteria, but K. pneumoniae strains were less susceptible. The MBC of FRPM against S. pneumoniae and the other strains tested equal and were within 1 dilution the MIC of that, respectively. These results suggest that FRPM has excellent in vitro bactericidal activity against clinical isolates and is a clinically useful for the chemotherapy of bacterial infections.
Matsuzaki
K
K
Chemotherapy Division, Mitsubishi-Kagaku Bio-Clinical Laboratories, Tokyo, Japan.
Nishiyama
T
T
Hasegawa
M
M
Kobayashi
I
I
Kaneko
A
A
Sasaki
J
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D007711:Klebsiella pneumoniae / Q000187:drug effects; D007769:Lactams; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D010462:Peptostreptococcus / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D047090:beta-Lactams; C107057:fropenem